Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects due to rising global demand and a robust pipeline. Recent stock weakness is overdone; valuation models show NVO trading at a significant discount, offering potential double-digit annual returns and dividend growth. The company's transition away from Hims & Hers and the upcoming oral Semaglutide launch position NVO for further market expansion and first-mover advantage.
NEW YORK , July 8, 2025 /PRNewswire/ -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Hims & Hers Health, Inc. (NYSE: HIMS) Shareholders should email Fletcher@fmoorelaw.com The investigation concerns a recent announcement about the Novo Nordisk collaboration. On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform.
Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its promised 2 billion-euro ($2.34 billion) investment in a factory south of Rome.
![]() NOVA 3 months ago | Other | €0.97 Per Share |
![]() NOVA 10 months ago | Other | €0.45 Per Share |
![]() NOVA 22 Mar 2024 | Other | €0.81 Per Share |
![]() NOVA 18 Aug 2023 | Other | €0.38 Per Share |
![]() NOVA 24 Mar 2023 | Other | €0.51 Per Share |
6 Aug 2025 (In 3 weeks) Date | | 6.04 Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
5 Feb 2025 Date | | - Cons. EPS | - EPS |
6 Nov 2024 Date | | - Cons. EPS | - EPS |
![]() NOVA 3 months ago | Other | €0.97 Per Share |
![]() NOVA 10 months ago | Other | €0.45 Per Share |
![]() NOVA 22 Mar 2024 | Other | €0.81 Per Share |
![]() NOVA 18 Aug 2023 | Other | €0.38 Per Share |
![]() NOVA 24 Mar 2023 | Other | €0.51 Per Share |
6 Aug 2025 (In 3 weeks) Date | | 6.04 Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
5 Feb 2025 Date | | - Cons. EPS | - EPS |
6 Nov 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Lars Fruergaard Jorgensen CEO | XMUN Exchange | US6701002056 ISIN |
DK Country | 77,406 Employees | 31 Mar 2025 Last Dividend | 20 Sep 2023 Last Split | - IPO Date |
Novo Nordisk A/S is an established global pharmaceutical company with a heritage dating back to 1923. With its headquarters in Bagsvaerd, Denmark, the company has a widespread operational reach across Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and other international markets. Novo Nordisk is committed to discovering and developing innovative pharmaceutical products, focusing primarily on Diabetes and Obesity Care, and Rare Disease. The company has carved a niche for itself by not just being a manufacturer but also engaging in the research and development of new pharmaceutical products, ensuring they provide contemporary and efficient solutions to the healthcare challenges of today.
Novo Nordisk A/S offers a comprehensive range of healthcare products and solutions aimed at addressing some of the most challenging diseases. With a focus on quality and innovation, their offerings encompass:
Through a collaboration agreement with Aspen Pharmaceuticals, Novo Nordisk also ensures the production of insulin products, highlighting their commitment to making essential medications accessible. The company's enduring legacy and forward-looking approach have positioned it as a key player in the global pharmaceutical industry, dedicated to improving the lives of patients worldwide.